F
F. Di Fiore
Researcher at French Institute of Health and Medical Research
Publications - 51
Citations - 1848
F. Di Fiore is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Colorectal cancer & Cetuximab. The author has an hindex of 18, co-authored 51 publications receiving 1728 citations. Previous affiliations of F. Di Fiore include University of Rouen.
Papers
More filters
Journal ArticleDOI
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.
F. Di Fiore,F. Blanchard,Françoise Charbonnier,F. Le Pessot,A. Lamy,M.P. Galais,L Bastit,Audrey Killian,Richard Sesboüé,Jean-Jacques Tuech,A.-M. Queuniet,Bernard Paillot,Jean-Christophe Sabourin,Francis Michot,Pierre Michel,Thierry Frebourg +15 more
TL;DR: It is confirmed that KRAS mutation is highly predictive of a non-response to cetuximab plus chemotherapy in MCRC and highlights the need to use sensitive molecular methods, such as SNaPshot or PCR-LCR assays, to ensure an efficient mutation detection.
Journal ArticleDOI
Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic.
Jean-Jacques Tuech,Alice Gangloff,F. Di Fiore,Pierre Michel,Cécile Brigand,Karem Slim,Marc Pocard,L. Schwarz +7 more
TL;DR: Most complex surgery with high morbidity and mortality–oesogastric, hepatic or pancreatic–is most often best deferred, and strategies can be proposed based on this comparison.
Journal ArticleDOI
Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer.
David Tougeron,F. Di Fiore,Sébastien Thureau,N. Berbera,I. Iwanicki-Caron,H. Hamidou,Bernard Paillot,Pierre Michel +7 more
TL;DR: It is suggested that CRT could be considered as an effective treatment without major toxicity in elderly patients with OC and Comorbidity index according to Charlson score was significantly associated with treatment tolerance.
Journal ArticleDOI
Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study.
T Aparicio,Magali Svrcek,Aziz Zaanan,Aziz Zaanan,E. Beohou,A. Laforest,Pauline Afchain,Emmanuel Mitry,Julien Taieb,F. Di Fiore,J.-M. Gornet,Anne Thirot-Bidault,Iradj Sobhani,David Malka,Thierry Lecomte,Clara Locher,F. Bonnetain,Pierre Laurent-Puig +17 more
TL;DR: This large study suggests that molecular alterations in SBA are closer to those in colorectal cancer (CRC) than those in gastric cancer, with low levels of HER 2 overexpression and high frequencies of KRAS mutations.
Journal ArticleDOI
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.
Alice Oden-Gangloff,F. Di Fiore,Frédéric Bibeau,Aude Lamy,Gaëlle Bougeard,Françoise Charbonnier,F. Blanchard,David Tougeron,Marc Ychou,F. Boissière,F. Le Pessot,J.-C. Sabourin,Jean-Jacques Tuech,Pierre Michel,Thierry Frebourg +14 more
TL;DR: TP53 mutations are predictive of cetuximab sensitivity, particularly in patients without KRAS mutation, and that TP53 genotyping could have a clinical interest to select patients who should benefit from cetUXimab-based CT.